NYSE:LLYPharmaceuticals
Is It Time To Reassess Eli Lilly (LLY) After GLP‑1 Obesity Drug Breakthroughs?
If you are wondering whether Eli Lilly's current share price fairly reflects its potential, you are not alone. This article will help you frame that question in a structured way.
At a last close of US$931.09, the stock has seen a 1.2% gain over the past 7 days, a 6.0% decline over 30 days, a 13.8% decline year to date, a 29.2% return over the past year and a very large gain over 5 years.
Recent news around Eli Lilly has focused heavily on its role in high profile therapeutic areas, including...